Molecules

Florbetaben

Target AmyloidClass Small molecule (stilbene)Other names BAY 94-9172

1ongoing trials
1radiolabelled forms
1approved products
590publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C21H26FNO3
Molar mass (g/mol)
358.4
Exact mass (Da)
358.1922
XLogP
4.2
H-bond donors
1
H-bond acceptors
5
Rotatable bonds
12
Heavy atoms
26
InChIKey
NCWZOASIUQVOFA-FWZJPQCDSA-N
PubChem record
CID 11501341 ↗
IUPAC name
4-[(E)-2-[4-[2-[2-(2-(18F)fluoroethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methyl(18F)aniline
SMILES
CNC1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)OCCOCCOCC[18F]

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁸F]florbetaben Syntheses and QC ↗Imaging358.41Phase 3Amyvid, Vizamyl, Neuraceq US EU FR JP

Ongoing trials · 1Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
Amyloid tracers2024-517942-33-03 · Cardiac amyloidosisPhase 3RecruitingFondazione Toscana Gabriele Monasterio1
Other trials listing it among the interventions (comparator, associated scan) · 8
ADRC PET · Amyloid tracersNCT07758660 · Alzheimer's disease and cognitive disordersPhase 2By invitationPatrick Lao1
ADVISe · Amyloid tracersNCT04576793 · Alzheimer's disease and cognitive disordersPhase 2RecruitingColumbia University1
TSPO tracersNCT04840979 · Alzheimer's disease and cognitive disordersPhase 2Active, not recruitingColumbia University1
Amyloid tracersNCT07787169 · Alzheimer's disease and cognitive disordersPhase 1RecruitingEli Lilly and Company3
Amyloid tracers2023-503705-10-00 · Alzheimer's disease and cognitive disordersPhase 1RecruitingDeutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.1
Amyloid tracersNCT04396873 · Alzheimer's disease and cognitive disordersPhase 1RecruitingNational Institute of Mental Health (NIMH)1
Amyloid tracersNCT07169630 · Alzheimer's disease and cognitive disordersPhase 1RecruitingNational Institute of Mental Health (NIMH)1
MGUS-PET · Amyloid tracersNCT07624760 · MyelomaNo phaseNot yet recruitingUniversity of Zurich1

PublicationsAll publications in PubMed ↗

590 publications in PubMed for the query below; the most recent:

florbetaben[tiab]

  1. Impact of adjunctive quantitative analysis on visual interpretation of amyloid PET: a multiple tracer, multicentre study Eur Radiol, 2026
  2. Atherosclerotic cardiovascular disease risk is associated with AT(N)V neuroimaging biomarkers and cognitive impairment in the health and aging brain study-health disparities cohort Front Aging Neurosci, 2026
  3. Distinct spatial patterns of perivascular spaces enlargement for multiple and Co-existing pathologies of cognitive impairment J Prev Alzheimers Dis, 2026
  4. Effects of apolipoprotein E ε4 on amyloid deposition and relative cerebral perfusion in cognitively normal individuals: a dual-phase 18 F-florbetaben PET study Nucl Med Commun, 2026
  5. Clinical utility of combined amyloid biomarkers in early cognitive impairment J Alzheimers Dis, 2026
  6. Comparison of Expert Reads Versus Local Clinical Reads of Amyloid PET Scans in the IDEAS Study J Nucl Med, 2026
  7. Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring Mol Diagn Ther, 2026
  8. Diagnostic Sensitivity of [18F]-Florbetaben-PET/CT in Detecting Cardiac Involvement in AL Amyloidosis: The Prospective MoRBiDA Study JACC Adv, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

Florbetaben. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/florbetaben/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.